WGS

GeneDx Holdings Corp. Class A Common Stock (WGS) | Rumor.io

GeneDx Holdings

WGS

Attention (50-day avg)0%

Attention rank (50-day avg)#901

Bullish sentiment (50-day avg)96%

Price to earnings ratio724.6

Market capitalization2.6B

Earnings per share-3.63

Dividend yield (TTM)—

Revenue (annual)427.5M

Net income (annual)-21M

Social

What share of all stock conversation is about WGS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% -0.01

Aug 4

GeneDx (WGS) has seen its price recover to $77 after initially falling to $55 following earnings, with management citing improving reimbursement issues and stable demand.
The company's commercial genome coverage increased to 87% from 47% in one quarter, and its annual recurring revenue (ARR) stopped falling, with Q3 guided up.
A Canaccord analyst raised the firm's price target on GeneDx to $90 from $75, driven by higher long-term estimates in their 10-year discounted cash flow model.

Generated by AI

Sentiment

Of the messages about WGS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -97.56	98.29% +2.84	92.27% +2.99
Bearish	—	100% +97.56	1.71% -2.84	7.73% -2.99

Bullish· May 6

Cathie Woods has invested a significant amount in GeneDx Holdings Corp. ($WGS), with an estimated $90 million, and continues to buy shares.
The stock is considered undervalued, with a price-to-sales ratio of 2 at 20%+ growth, making it a deep value opportunity.
The company has a solid testing volume, is launching new products, and has a large addressable market (TAM) to address, with favorable reimbursement being a key element for future growth.

Bearish· May 5

GeneDx Holdings Corp. reported a Q1 loss of $0.28 per share, $0.27 worse than expected, with revenues rising 17.5% year/year to $102.3 million.
The company issued downside guidance for Q2, expecting revenues of $110-112 million, lower than the $130.30 million consensus.
BTIG lowered its price target on GeneDx Holdings from $170 to $90, and the CEO has sold millions of dollars worth of shares, further exacerbating concerns about the company's financial health.

Generated by AI

Topics

Of the messages about WGS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	0.77%	59.32%
Technical Analysis	—	0%	5.38%	12.66%
Analysts	—	0%	46.92%	11.52%
Earnings	—	0%	0%	4.66%
Macro	—	0%	46.92%	11.62%
Controversies	—	0%	0%	0.22%

Announcements· Feb 23

GeneDx Holdings Corp. (WGS) reported Q4 2025 earnings, with revenue of $121.0M, exceeding estimates by $1.0M, and a 26.50% YoY growth.
The company reaffirmed its FY26 guidance, expecting revenue to range between $540M to $555M, vs. FactSet estimate of $538.8M.
GeneDx's exome and genome revenue grew 32% YoY to $104.00M, with volume up 34.3% and adjusted gross margin expanding to 71%.

Technical Analysis· Apr 30

$WGS is down 41.5% to $68.43, setting the biggest one-day fall on record, after posting Q1 revenue of $87.1 million, down 8.6% from the previous quarter.
The stock is technically still in a base relative to its previous levels, but has overhead supply all the way to $117, with most of the volume going to the sell side after the gap.
$WGS is currently holding support at the 200-day SMA, with some analysts expecting a bounce, but others advising to wait for a few more days before buying.

Generated by AI

Community

Of the messages about WGS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25%	47.06%	70.34%	57.72%
Newcomers	75%	52.94%	29.66%	42.28%

Regulars· Feb 23

GeneDx Holdings Corp. reported Q4 2025 revenues of $121.0 million, with a 32% year-over-year growth in exome and genome test revenue, and accelerated exome and genome volume growth to 34% year-over-year.
Analysts maintain a positive outlook on GeneDx, with targets ranging from $150 to $170, citing strong Q4 results and good guidance for 2026, with growth momentum continuing and 2026 expected to be the strongest year in the company's history.
Despite a net loss in Q4, GeneDx's stock is up 7% in pre-market trading, with analysts pointing to the company's strong growth momentum and the potential for a 20-30% up day if the market had a green day.

Newcomers· Mar 6

Director Meister Keith A. of GeneDx Holdings Corp. purchased 169,521 shares worth $13.46M at an average price of $79.40, deploying a "buy the panic" signal after a sharp post-earnings drawdown.
GeneDx Holdings Corp. is scaling pediatric whole-exome sequencing and whole-genome sequencing with a defensible data moat in its Infinity platform, with FY25 revenue growing 41% and adjusted gross margin at 71%.
GeneDx Holdings Corp.'s growth is making waves in genetic testing, with 70% YoY growth, and its defensible data moat in pediatric diagnostics could make it the next big player in the industry.

Generated by AI

News

GeneDx CEO Katherine Stueland sells $1.03m in stock

11d agoInvesting.com

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

GAITHERSBURG, Md., September 09, 2026--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

20d agoYahoo Finance

GeneDx at Wells Fargo healthcare conference: growth and collections in focus

21d agoInvesting.com

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

GAITHERSBURG, Md., September 01, 2026--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity

29d agoYahoo! Finance Canada

GeneDx study shows rapid genome sequencing benefits beyond ICUs

1mo agoInvesting.com

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

GAITHERSBURG, Md., August 24, 2026--GeneDx and Seattle Children’s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.

1mo agoYahoo Finance Singapore

Also Discussed

Investors talking about WGS also mention

#	Name	Attention
1	Personalis Inc.PSNL	0%-0.01
2	Natera, Inc.NTRA	0%-0.01
3	Guardant Health Inc.GH	0%-0.11
4	Lyell Immunopharma, Inc.LYEL	0.01%new
5	Surgery Partners Inc.SGRY	0%0
6	Webster Financial CorporationWBS	0%new
7	SkyWest Inc.SKYW	0%new
8	CIVI - Civitas Resources, Inc.	——
9	Customers Bancorp Inc.CUBI	0%0
10	STAI - ScanTech AI Systems Inc.	——

GeneDx Holdings Corp. Class A Common Stock

Healthcare
Diagnostics & Research

GeneDx Holdings Corp. Class A Common Stock is the equity security of GeneDx Holdings Corp., a genomics company focused on genetic testing and clinical diagnostics. GeneDx provides pediatric and rare disease testing centered on whole exome and whole genome sequencing, along with data and information services that support more precise diagnosis and care decisions. The company also offers AI-enabled tools for sequencing analysis, interpretation, and clinical reporting across rare disease, hereditary risk, and cancer testing. Its services are used by clinicians, hospitals, and healthcare organizations that rely on genomic information to guide patient evaluation and treatment. GeneDx Holdings Corp. plays a specialized role in the healthcare market by combining laboratory testing, bioinformatics, and clinical expertise to deliver actionable genetic insights for complex medical cases.

Website

Location

North Tower

Stamford, CT, 06902

United States

Social

What share of all stock conversation is about WGS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% -0.01

Aug 4

GeneDx (WGS) has seen its price recover to $77 after initially falling to $55 following earnings, with management citing improving reimbursement issues and stable demand.
The company's commercial genome coverage increased to 87% from 47% in one quarter, and its annual recurring revenue (ARR) stopped falling, with Q3 guided up.
A Canaccord analyst raised the firm's price target on GeneDx to $90 from $75, driven by higher long-term estimates in their 10-year discounted cash flow model.

Generated by AI

Sentiment

Of the messages about WGS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -97.56	98.29% +2.84	92.27% +2.99
Bearish	—	100% +97.56	1.71% -2.84	7.73% -2.99

Bullish· May 6

Cathie Woods has invested a significant amount in GeneDx Holdings Corp. ($WGS), with an estimated $90 million, and continues to buy shares.
The stock is considered undervalued, with a price-to-sales ratio of 2 at 20%+ growth, making it a deep value opportunity.
The company has a solid testing volume, is launching new products, and has a large addressable market (TAM) to address, with favorable reimbursement being a key element for future growth.

Bearish· May 5

GeneDx Holdings Corp. reported a Q1 loss of $0.28 per share, $0.27 worse than expected, with revenues rising 17.5% year/year to $102.3 million.
The company issued downside guidance for Q2, expecting revenues of $110-112 million, lower than the $130.30 million consensus.
BTIG lowered its price target on GeneDx Holdings from $170 to $90, and the CEO has sold millions of dollars worth of shares, further exacerbating concerns about the company's financial health.

Generated by AI

Topics

Of the messages about WGS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	0.77%	59.32%
Technical Analysis	—	0%	5.38%	12.66%
Analysts	—	0%	46.92%	11.52%
Earnings	—	0%	0%	4.66%
Macro	—	0%	46.92%	11.62%
Controversies	—	0%	0%	0.22%

Announcements· Feb 23

GeneDx Holdings Corp. (WGS) reported Q4 2025 earnings, with revenue of $121.0M, exceeding estimates by $1.0M, and a 26.50% YoY growth.
The company reaffirmed its FY26 guidance, expecting revenue to range between $540M to $555M, vs. FactSet estimate of $538.8M.
GeneDx's exome and genome revenue grew 32% YoY to $104.00M, with volume up 34.3% and adjusted gross margin expanding to 71%.

Technical Analysis· Apr 30

$WGS is down 41.5% to $68.43, setting the biggest one-day fall on record, after posting Q1 revenue of $87.1 million, down 8.6% from the previous quarter.
The stock is technically still in a base relative to its previous levels, but has overhead supply all the way to $117, with most of the volume going to the sell side after the gap.
$WGS is currently holding support at the 200-day SMA, with some analysts expecting a bounce, but others advising to wait for a few more days before buying.

Generated by AI

Community

Of the messages about WGS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25%	47.06%	70.34%	57.72%
Newcomers	75%	52.94%	29.66%	42.28%

Regulars· Feb 23

GeneDx Holdings Corp. reported Q4 2025 revenues of $121.0 million, with a 32% year-over-year growth in exome and genome test revenue, and accelerated exome and genome volume growth to 34% year-over-year.
Analysts maintain a positive outlook on GeneDx, with targets ranging from $150 to $170, citing strong Q4 results and good guidance for 2026, with growth momentum continuing and 2026 expected to be the strongest year in the company's history.
Despite a net loss in Q4, GeneDx's stock is up 7% in pre-market trading, with analysts pointing to the company's strong growth momentum and the potential for a 20-30% up day if the market had a green day.

Newcomers· Mar 6

Director Meister Keith A. of GeneDx Holdings Corp. purchased 169,521 shares worth $13.46M at an average price of $79.40, deploying a "buy the panic" signal after a sharp post-earnings drawdown.
GeneDx Holdings Corp. is scaling pediatric whole-exome sequencing and whole-genome sequencing with a defensible data moat in its Infinity platform, with FY25 revenue growing 41% and adjusted gross margin at 71%.
GeneDx Holdings Corp.'s growth is making waves in genetic testing, with 70% YoY growth, and its defensible data moat in pediatric diagnostics could make it the next big player in the industry.

Generated by AI

GeneDx Holdings

Social

Aug 4

Bullish· May 6

Bearish· May 5

Announcements· Feb 23

Technical Analysis· Apr 30

Regulars· Feb 23

Newcomers· Mar 6

GeneDx CEO Katherine Stueland sells $1.03m in stock

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

GeneDx at Wells Fargo healthcare conference: growth and collections in focus

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

GeneDx study shows rapid genome sequencing benefits beyond ICUs

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Also Discussed

GeneDx Holdings Corp. Class A Common Stock

Company Information

Location

GeneDx CEO Katherine Stueland sells $1.03m in stock

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

GeneDx at Wells Fargo healthcare conference: growth and collections in focus

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

GeneDx study shows rapid genome sequencing benefits beyond ICUs

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

Also Discussed

Social

Aug 4

Bullish· May 6

Bearish· May 5

Announcements· Feb 23

Technical Analysis· Apr 30

Regulars· Feb 23

Newcomers· Mar 6